{"product_id":"passagebio-bcg-matrix","title":"Passage Bio Boston Consulting Group Matrix","description":"\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDetailed BCG Matrix assessment, guiding investment, holding, or divestment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCustomizable BCG matrix that simplifies complex data with a visually-appealing format.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You’re Viewing Is Included\u003c\/span\u003e\u003cbr\u003ePassage Bio BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe BCG Matrix you're previewing is identical to the purchased version. This comprehensive document is ready for immediate use, offering strategic insights without any alterations. Receive the complete, professionally designed matrix after purchase.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003ch2\u003eBCG Matrix Template\u003c\/h2\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThe Passage Bio BCG Matrix offers a glimpse into the company's product portfolio. See how its offerings are categorized as Stars, Cash Cows, Dogs, and Question Marks. This preview is just the beginning. Get the full BCG Matrix report to uncover detailed quadrant placements, data-backed recommendations, and a roadmap to smart investment and product decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePBFT02 for FTD-GRN\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePBFT02, Passage Bio's lead candidate, targets frontotemporal dementia (FTD) linked to progranulin deficiency. The upliFT-D trial's interim data revealed sustained CSF PGRN level increases. It also showed early signs of improvement in a disease progression biomarker. Success hinges on continued positive data and regulatory support, potentially leading to market leadership. Passage Bio's market cap was around $110 million as of late 2024. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAAV-delivered Gene Therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePassage Bio concentrates on AAV-delivered gene therapies, which are gaining traction as innovative treatments. They have a strategic partnership with Catalent for manufacturing. The gene therapy market, valued at $4.8B in 2023, is expected to grow. Passage Bio's focus on rare CNS disorders positions them well to benefit from market growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaboration with Gemma Biotherapeutics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePassage Bio's collaboration with Gemma Biotherapeutics focuses on preclinical and IND-enabling work for Huntington's disease and other CNS indications. This partnership leverages external expertise and expands Passage Bio's pipeline. The Huntington's disease market could reach $2.5 billion by 2028, and successful programs could generate substantial revenue. This collaboration is a strategic move for future growth. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Manufacturing Capabilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePassage Bio's partnership with Catalent and its manufacturing process for PBFT02 are significant strengths. This collaboration supports efficient and scalable production, vital for gene therapy demand. Their manufacturing prowess is crucial for late-stage development and commercialization success. This positions them well in the competitive landscape. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eCatalent's partnership provides access to advanced manufacturing technologies.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eHigh-productivity, suspension-based manufacturing enhances scalability.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eEfficient manufacturing is crucial for commercial viability.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThis positions Passage Bio strongly for late-stage development.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpansion into FTD-C9orf72\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePassage Bio's expansion of the upliFT-D trial to include FTD-C9orf72 patients broadens its scope. This strategic decision targets a wider patient group within the FTD market. Success in this expanded trial could significantly boost PBFT02's market standing. This approach aligns with the $100 million in cash, cash equivalents, and marketable securities reported as of September 30, 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eWider Patient Reach:\u003c\/strong\u003e Targeting a larger FTD patient pool.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Position:\u003c\/strong\u003e Aiming to improve PBFT02's market value.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFinancials:\u003c\/strong\u003e Leveraging $100M+ in liquid assets.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Goal:\u003c\/strong\u003e Expanding therapeutic opportunities.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePBFT02: A Star in Gene Therapy's Expanding Universe!\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePassage Bio's PBFT02, with promising trial data, is a Star in the BCG matrix. It is well-positioned in the growing gene therapy market, expected to reach $11.7 billion by 2028. Their strategic partnerships support manufacturing and pipeline expansion. This positions them for significant future growth and market leadership in rare CNS disorders.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eBCG Matrix\u003c\/th\u003e\n\u003cth\u003ePassage Bio\u003c\/th\u003e\n\u003cth\u003eKey Metrics (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eStars\u003c\/td\u003e\n\u003ctd\u003ePBFT02\u003c\/td\u003e\n\u003ctd\u003eMarket Cap: ~$110M, Cash: $100M+, Gene Therapy Market: $4.8B (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartnerships\u003c\/td\u003e\n\u003ctd\u003eCatalent, Gemma\u003c\/td\u003e\n\u003ctd\u003eManufacturing \u0026amp; Pipeline Expansion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFocus\u003c\/td\u003e\n\u003ctd\u003eFTD, Huntington's\u003c\/td\u003e\n\u003ctd\u003eTargeting rare CNS disorders\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Outlook\u003c\/td\u003e\n\u003ctd\u003eStrong Growth\u003c\/td\u003e\n\u003ctd\u003eHD Market: $2.5B (2028)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOut-licensed Pediatric Lysosomal Storage Disease Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePassage Bio's out-licensed pediatric lysosomal storage disease programs, now with Gemma Biotherapeutics, offer financial benefits. Initial payments and potential milestones from Gemma contribute to Passage Bio's cash flow. This supports the company's main programs, even without active development. In 2024, Passage Bio's collaboration with Gemma is expected to generate $20 million.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePassage Bio's intellectual property (IP) portfolio includes patents and applications for AAV capsids and gene therapy methods. This IP strengthens their competitive edge, potentially generating revenue through licensing agreements. Robust IP protection is crucial, especially in attracting collaborations. In 2024, the biotech sector saw significant IP-related deals, with licensing revenues demonstrating the importance of protecting innovations. The value of strong IP is consistently highlighted in biotech valuations and partnerships.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStrategic alliances, like the Gemma Biotherapeutics collaboration, offer Passage Bio a stable revenue source with moderate growth. These partnerships often involve sharing resources or technology, which can boost financial stability. In 2024, such collaborations generated approximately $5 million in revenue for similar biotech companies, demonstrating their financial impact. This allows Passage Bio to concentrate on its main drug development pipeline.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHEK293 cell-based AAV Production Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePassage Bio's HEK293 cell-based AAV production platform, utilizing the iCELLis bioreactor, is a key asset for their AAV product candidates. This platform presents an opportunity for licensing to other companies, offering a potential revenue stream. This strategy allows Passage Bio to generate income while concentrating on its main therapeutic pipeline. The platform's scalability and efficiency could attract significant interest, boosting financial flexibility.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003e2023 saw the AAV market valued at approximately $4.7 billion.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eLicensing revenue models can vary, but typically include upfront payments, milestones, and royalties on sales.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eiCELLis bioreactors are known for their high cell densities, which improve production efficiency.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThis platform is crucial for the development and manufacturing of gene therapies.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStable Cash Runway\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePassage Bio, categorized as a \"Cash Cow\" in the BCG Matrix, demonstrates a stable cash runway. They've extended their financial resources into Q1 2027 through cost-saving strategies. This financial health supports their long-term development plans, which is crucial for attracting investment. As of Q3 2024, they reported $192.4 million in cash, cash equivalents, and marketable securities.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eCash Runway: Extended to Q1 2027.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eFinancial Health: Supports long-term development.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eQ3 2024 Financials: $192.4M in liquid assets.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eStrategic Focus: Cost-cutting and investment attraction.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBio's $192.4M Cash Fuels Growth \u0026amp; Gemma Deal's $20M Boost!\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePassage Bio, as a Cash Cow, shows financial stability through its out-licensed programs and collaborations, like the Gemma deal generating $20 million in 2024.\u003c\/p\u003e\n\u003cp\u003eTheir strong IP and AAV production platform offer additional revenue streams, enhancing their financial position. This financial health is supported by a cash runway extended to Q1 2027, and a solid liquid asset base.\u003c\/p\u003e\n\u003cp\u003eThey reported $192.4 million in cash and equivalents as of Q3 2024, enabling long-term development and investment attraction.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct orange_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Aspect\u003c\/th\u003e\n\u003cth\u003eDetails\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGemma Collaboration (2024)\u003c\/td\u003e\n\u003ctd\u003e$20M revenue\u003c\/td\u003e\n\u003ctd\u003eSupports cash flow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Runway\u003c\/td\u003e\n\u003ctd\u003eExtended to Q1 2027\u003c\/td\u003e\n\u003ctd\u003eEnsures long-term development\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2024 Liquid Assets\u003c\/td\u003e\n\u003ctd\u003e$192.4M\u003c\/td\u003e\n\u003ctd\u003eFunds operations, attracts investors\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePBGM01 for GM1 Gangliosidosis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePBGM01, targeting GM1 Gangliosidosis, was out-licensed to Gemma Biotherapeutics. Passage Bio shifted focus to core CNS programs. The near-term value generation by PBGM01 directly for Passage Bio is now unlikely. In 2024, there is no revenue from PBGM01 for Passage Bio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePBKR03 for Krabbe Disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePBKR03, like PBGM01, was out-licensed for Krabbe Disease. It has low market share due to limited internal resources. Investment is unlikely unless Gemma Biotherapeutics progresses significantly. Passage Bio's focus shifted away from this asset in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePBML04 for Metachromatic Leukodystrophy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePBML04, like other Passage Bio assets, was out-licensed to Gemma Biotherapeutics. Its value now hinges on Gemma's execution, offering minimal immediate financial impact for Passage Bio. Considering the out-licensing, it's not expected to substantially boost Passage Bio's revenue in the short term. In 2024, Passage Bio's focus is on other programs. The success of PBML04 is now in Gemma's hands.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEarly Stage Preclinical Programs with no immediate focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEarly-stage preclinical programs, not Passage Bio's primary focus, fall into the \"Dogs\" quadrant of a BCG matrix. These programs, with low market share, exist in potentially low-growth markets, requiring significant investments. Considering that in 2024, the biotech sector faced funding challenges, these programs' returns are uncertain. Passage Bio's financial reports reflect this strategic prioritization. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eLow market share and growth potential characterize these programs.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eSignificant investment is necessary for preclinical development.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eReturns on investment are uncertain in the current market.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eFinancial data from 2024 highlights resource allocation decisions.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrograms targeting very small patient populations with limited commercial viability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePrograms for very small patient populations face tough market challenges. These programs often struggle to gain traction due to limited market reach. High development and manufacturing costs, especially for gene therapies, can make these ventures unprofitable. Companies might deprioritize them for more commercially viable options. In 2024, the FDA approved only a handful of ultra-rare disease therapies, reflecting these challenges.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eMarket penetration is inherently limited by patient numbers.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eHigh R\u0026amp;D costs and manufacturing expenses are significant burdens.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eCommercial attractiveness often dictates resource allocation.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eRegulatory hurdles can also impact viability.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDog Programs: Low Share, High Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs quadrant programs have low market share and face growth uncertainties. They demand considerable investment in preclinical phases. Given biotech funding challenges in 2024, returns are unpredictable.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eCharacteristic\u003c\/th\u003e\n\u003cth\u003eDetails\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Share\u003c\/td\u003e\n\u003ctd\u003eLow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGrowth Potential\u003c\/td\u003e\n\u003ctd\u003eUncertain\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInvestment Needs\u003c\/td\u003e\n\u003ctd\u003eSignificant\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePBFT02 for ALS\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePassage Bio is investigating PBFT02 for amyotrophic lateral sclerosis (ALS). ALS treatment faces considerable unmet needs, but PBFT02's development path is unclear. The ALS treatment market was valued at $487 million in 2023. Clinical trials and regulatory feedback will shape its market potential. Market size is projected to reach $784 million by 2028.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePBFT02 for Alzheimer's Disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePBFT02 is under investigation for Alzheimer's disease. This market is large, yet competitive. Success is uncertain, as further research is needed. The Alzheimer's market was valued at $4.06 billion in 2023. About 6.7 million Americans aged 65 and older live with Alzheimer's.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNew CNS Indications from Gemma Collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePassage Bio's collaboration with Gemma Biotherapeutics opens doors to four potential new CNS indications. These opportunities expand beyond Huntington's disease, signaling growth potential, but specifics like market size and timelines are unclear. The biotech sector saw significant investment in 2024, with over $25 billion raised in Q3 alone, suggesting a dynamic environment for such ventures. Strategic decisions and further research will shape the future of these indications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartnerships for new delivery method\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNovel delivery methods for gene therapies could be transformative. If Passage Bio invests in, or partners on, new delivery tech, it's a big, risky move. Success hinges on the tech's effectiveness and how widely it's used. Such ventures demand substantial capital with outcomes that are not guaranteed.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003ePassage Bio's R\u0026amp;D spending in 2024 was approximately $75 million.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThe gene therapy market is projected to reach $11.6 billion by 2028.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003ePartnerships can reduce risk but also dilute potential profit.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eDelivery method innovation can significantly boost efficacy rates.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpansion to new neurodegenerative diseases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVenturing into new neurodegenerative diseases, beyond FTD and ALS, positions Passage Bio as a Question Mark within its BCG matrix. This strategic move necessitates substantial investment in research and development, potentially impacting the company's financial resources. Success hinges on the specific diseases targeted and the competitive environment, with the potential for high returns but also significant risks. The company's ability to secure funding and navigate clinical trials will be crucial.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eR\u0026amp;D spending in the biotech industry rose to $168 billion in 2023.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThe Alzheimer's drug market alone is projected to reach $13.7 billion by 2027.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eClinical trial failure rates in neurodegenerative diseases can exceed 80%.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeurodegenerative Diseases: A Risky Venture?\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePassage Bio's exploration of new neurodegenerative diseases, places it as a \"Question Mark.\" This strategy demands significant R\u0026amp;D investments, potentially affecting finances. Success depends on the targeted diseases, competitive landscapes, and the company's funding abilities.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct orange_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eDetails\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Spend (2024)\u003c\/td\u003e\n\u003ctd\u003eApprox. $75 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiotech R\u0026amp;D Spend (2023)\u003c\/td\u003e\n\u003ctd\u003e$168 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAlzheimer's Market (2027)\u003c\/td\u003e\n\u003ctd\u003e$13.7 billion (projected)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003ch2\u003eBCG Matrix \u003cspan style=\"color: #FB9C46;\"\u003eData Sources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003cp\u003eThis Passage Bio BCG Matrix relies on financial reports, clinical trial data, competitor analysis, and market assessments for evidence-based decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Data-Sources.svg\" alt=\"Data Sources\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"SAE","offers":[{"title":"Default Title","offer_id":56070233850240,"sku":"passagebio-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0899\/6510\/1440\/files\/passagebio-bcg-matrix.png?v=1749414695","url":"https:\/\/swotanalysistemplates.com\/products\/passagebio-bcg-matrix","provider":"SWOT Analysis Templates","version":"1.0","type":"link"}